Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 2/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
| ▸ | CRHBP | P24387 | 1/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL944650 | 0.84 | SCN4A (0.32) | SCN4ARAPGEF4TSHR | |
| SCHEMBL944592 | 0.83 | — | — | |
| SCHEMBL944232 | 0.77 | — | — | |
| SCHEMBL10899786 | 0.75 | ALDH1A1 (0.41) | TSHRTP53CYP3A4 | |
| SCHEMBL25439064 | 0.73 | ATP4A (0.37) | SCN4ATSHRTP53CYP3A4 | |
| SCHEMBL21472699 | 0.72 | RAPGEF4 (0.40) | SCN4ARAPGEF4TSHRCYP3A4CES1 | |
| SCHEMBL14524295 | 0.72 | TSHR (0.37) | SCN4ARAPGEF4TSHRCYP3A4CES1 | |
| SCHEMBL13242368 | 0.71 | L3MBTL1 (0.33) | TSHR | |
| SCHEMBL5729221 | 0.70 | TSHR (0.35) | SCN4ARAPGEF4TSHRCYP3A4CES1 | |
| SCHEMBL6354293 | 0.70 | TSHR (0.35) | SCN4ARAPGEF4TSHRCYP3A4CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875753-B2 | formed by reacting aryldiazonium bromide with vinylidene chloride in presence of copper salt and bromide source | BAYER CROPSCIENCE AG (DE) | 2011-01-25 | — | — | US | disclosed |
| US-7875753-B2 | formed by reacting aryldiazonium bromide with vinylidene chloride in presence of copper salt and bromide source | BAYER CROPSCIENCE AG (DE) | 2011-01-25 | — | — | US | disclosed |
| US-7875753-B2 | formed by reacting aryldiazonium bromide with vinylidene chloride in presence of copper salt and bromide source | BAYER CROPSCIENCE AG (DE) | 2011-01-25 | — | — | US | disclosed |
| WO-2010105739-A1 | AROMATIC 2-BROMO-2,2-DICHLOROETHYL COMPOUNDS AND METHODS FOR THE PRODUCTION THEREOF | BAYER CROPSCIENCE AG (DE) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010105739-A1 | AROMATIC 2-BROMO-2,2-DICHLOROETHYL COMPOUNDS AND METHODS FOR THE PRODUCTION THEREOF | BAYER CROPSCIENCE AG (DE) | 2010-09-23 | — | — | WO | disclosed |
| US-20100234651-A1 | 2-Bromo-2,2-Dichloroethyl Aromatics and Process for Preparation Thereof | BAYER CROPSCIENCE AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234651-A1 | 2-Bromo-2,2-Dichloroethyl Aromatics and Process for Preparation Thereof | BAYER CROPSCIENCE AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234651-A1 | 2-Bromo-2,2-Dichloroethyl Aromatics and Process for Preparation Thereof | BAYER CROPSCIENCE AG (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234651-A1 | 2-Bromo-2,2-Dichloroethyl Aromatics and Process for Preparation Thereof | AR, AHR, ADRA2C | SCN4A 2729/4885RAPGEF4 1795/4885TSHR 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.